Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

December 16, 2024

Conditions
Rheumatoid ArthritisSpondyloarthritisPsoriatic Arthritis
Interventions
OTHER

collection of clinical parameters and blood sample

"* A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."

Trial Locations (1)

75014

Rheumatology Department, Cochin Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER